ID Source | ID |
---|---|
PubMed CID | 173253 |
MeSH ID | M0127151 |
Synonym |
---|
beta-casomorphin 4 |
(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid |
74171-19-0 |
beta-casomorphin 4 (ox) |
tyr-pro-phe-pro |
1-(n-(1-l-tyrosyl-l-prolyl)-l-phenylalanyl)-l-proline |
l-proline, 1-(n-(1-l-tyrosyl-l-prolyl)-l-phenylalanyl)- |
tyrosyl-prolyl-phenylalanyl-proline |
DTXSID70225142 |
l-tyr-pro-phe-pro |
beta-casomorphin(1-4)(bovine) |
(s)-1-((s)-2-((s)-1-((s)-2-amino-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboxamido)-3-phenylpropanoyl)pyrrolidine-2-carboxylic acid |
l-tyrosyl-l-prolyl-l-phenylalanyl-l-proline |
AKOS040746618 |
Excerpt | Relevance | Reference |
---|---|---|
" Analysis of the slopes of the dose-response curves seems to suggest that differences between the activity of these opioid peptides in SHR and WAG rats are based on a difference in the density and affinity of the subpopulation of the opioid receptors in these strains of rats." | ( Analgesic activity of morphiceptin, beta-casomorphin-4, and deltakephalin in normotensive Wistar-Glaxo and spontaneously hypertensive rats. Członkowski, A; Widy-Tyszkiewicz, E, ) | 0.13 |
" Only beta-CM5 was effective, and the dose-response relationship was graded." | ( beta-Casomorphin causes hypoalgesia in 10-day-old rats: evidence for central mediation. Blass, EM; Blom, J, 1996) | 0.29 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.17) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |